Safety and Effectiveness of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer in Real-World Settings: First Observations from an Interdisciplinary Breast Cancer Centre in Germany

This study observed the real-world safety and effectiveness of sacituzumab govitecan in 43 patients with metastatic triple-negative breast cancer at a German breast cancer center. Patients received a median of 5 cycles of treatment and were followed for a median of 12.9 months. Common adverse events included alopecia (90.7%), diarrhoea (37.2%), and fatigue (34.9%). Severe adverse events included neutropenia (27.9%) and diarrhoea (18.6%). Dose adjustments were necessary for 25 patients due to adverse events or pre-existing conditions. The median progression-free survival was 5.0 months, and the median overall survival was 13.1 months. The findings aligned with clinical trial data, but further studies were suggested to optimize treatment and manage adverse events.